title: Complete remission of a primary cutaneous follicle-center cell lymphoma (EORTC criteria)/diffuse large B-cell lymphoma (WHO criteria) by single first-line therapy with rituximab.
authors.forename: Akiko
authors.initials: A
authors.lastname: Nagasaka
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Matsue
authors.forename: Tatsuyoshi
authors.initials: T
authors.lastname: Kawamura
authors.forename: Mirei
authors.initials: M
authors.lastname: Kanzaki
authors.forename: Takashi
authors.initials: T
authors.lastname: Inozume
authors.forename: Yuumi
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Akira
authors.initials: A
authors.lastname: Shimzu
authors.forename: Naotaka
authors.initials: N
authors.lastname: Shibagaki
authors.forename: Mitsuaki
authors.initials: M
authors.lastname: Yanagi
authors.forename: Shinji
authors.initials: S
authors.lastname: Shimada
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001365:Axilla / Q000473:pathology; D003937:Diagnosis, Differential; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D016393:Lymphoma, B-Cell / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D000069283:Rituximab; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab